danuglipron + itraconazole

Danuglipron + itraconazole refers to the co-administration of **danuglipron**, an investigational oral small molecule glucagon-like peptide 1 receptor (GLP-1R) agonist, and **itraconazole**, an antifungal agent that acts as a potent inhibitor of cytochrome P450 3A4 (CYP3A4). Danuglipron has been developed for the treatment of type 2 diabetes and obesity, functioning by stimulating GLP-1R to enhance glucose-dependent insulin release and reduce food intake. Itraconazole is clinically approved for treatment of fungal infections and is widely used in pharmacokinetic interaction studies due to its strong CYP3A4 inhibition, which can significantly increase exposure to drugs metabolized by this pathway. The specific combination "danuglipron + itraconazole" has been studied in healthy volunteers to investigate the impact of itraconazole on the pharmacokinetics of danuglipron, not as a therapeutic combination but to predict potential drug-drug interactions for future danuglipron use[1][3][5].